________________________________________________________________________________________________________________________________

© Wolf G Kroner 2017 - Dr. Ursula B. Redeker Roche prepares itself for user innovation

December 2017. The efficiency and quality of point-of-care diagnostics and personalised medicine crucially depend on local knowledge. Life sciences or biotechnology fall short of promises, if they are not complemented. Digital tools may fill the gap, but, ironically, the success of universal technologies is intimately tied to the particular geography of their use.

B2Bioworld asked Ursula Redeker, CEO of Roche Germany about her perspective. “I can imagine a shift and additions in skill sets” predicts Ursula Redeker, CEO of Roche Germany. In the exclusive interview with B2Bioworld she outlines in-house gaps, envisaged partnerships, and describes her current thinking of future healthcare in the context of Roche Europe.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Article free of advertisement

Full Company License enquire here

Please note, this interview is included in Masters of Health, published February 2018.

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Regulatory Challenges of Big Data Operations – Algorithms, Healthcare, or Autonomous Driving
Herbert Zech, Professor of Life Sciences and Intellectual Property Laws at Universität Basel on key juridical concepts of the current debate about big data and artificial intelligence applications beyond privacy laws

Steering Health Data For or By?
The User as Stakeholder, Expert, Citizen, Consumer, and Patient. Tomas D. Szucs, Chairman of Helsana Group, one of the largest Swiss health insurance companies, on making “big data” work and crossing traditional boundaries of managing information assets

Clarifying the concept of personalised medicine: Stem Cells - a discovery tool and a potential therapeutic modality
Jonathan Knowles, past Member of the Roche Executive Committee and Head of Group Research

Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Transition: Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Adhering to Values Pays Off
Novartis continues to expand the biotech therapeutics pipeline / Focus on emerging markets

Patient-centered Precision Care
Michael Christman, President of Coriell Institute about turning research on human genotyping into healthcare routine

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, past Chief Technology Officer Life Sciences at Tecan on electrowetting technology, blood diagnostic devices, weaknesses of competitors like Illumina, and prospects of clinical microfluidics

Opening up Emerging Markets for Rapid Diagnostics and Point-of-Care Assays
David Dolinger shares experience and insight. Do’s and don’ts in developing viable tests for medical, agricultural, or food diagnostics, and bringing these to low resource countries.

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle